An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma
The EGFR mutation, ALK fusion gene, and MET exon 14 skipping mutation were detected in patients with pulmonary sarcomatoid carcinoma in clinical practice, and some patients achieved long survival times after receiving targeted therapy. Further investigation is necessary to evaluate the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma.
Authors
- Nozomu Murayama
- Zenta Seto
- Kenji Azechi
- Ryuji Hayashi (ORCID: https://orcid.org/0000-0002-4205-9540)
- Shoko Matsui (ORCID: https://orcid.org/0000-0002-1328-5768)
- Seisuke Okazawa (ORCID: https://orcid.org/0000-0002-2592-7131)
- Hirokazu Taniguchi (ORCID: https://orcid.org/0000-0003-2414-8344)
- Kenta Kambara
- Tomomi Ichikawa (ORCID: https://orcid.org/0000-0002-3998-0216)
- Yasuaki Masaki (ORCID: https://orcid.org/0000-0001-7001-9725)
- Chihiro Taka
- Minehiko Inomata (ORCID: https://orcid.org/0000-0002-6846-187X)
- Naoki Takata (ORCID: https://orcid.org/0000-0002-8479-8165)
- Takeshi Tsuda (ORCID: https://orcid.org/0000-0002-6243-4459)
- Isami Mizusihima
- Masahiro Matsumoto
- Kotaro Tokui
- Toshiro Miwa
- Takahiro Hirai
- Shingo Imanishi
- Kana Hayashi
Institutions
- Toyama Prefectural Central Hospital (JP)
- Toyama City Hospital (JP)
- Toyama University Hospital (JP)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s12672-024-01046-5
- Citations
- 1
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- University of Toyama